Antitumor agent-169
Antitumor agent-169 (Compound B3) is a dual inhibitor PD-1/PD-L1 interaction and PARP7, with IC50s of 0.426 μM and 2.50 nM. Antitumor agent-169 exhibits an affinity to human PD-L1, with Ki of 20.2 nM. Antitumor agent-169 restores the T cell function, increases IFN-γ secretion. Antitumor agent-169 inhibits cell viability of MDA-MB-231 and Jurkat T, exhibits antitumor efficacy against melanoma in mouse model and good pharmacokinetic characteristics[1].
Product Specifications
CAS Number
[9007-83-4]
UNSPSC
12352005
Target
PARP; PD-1/PD-L1
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/antitumor-agent-169.html
Smiles
CC1=C(C=CC=C1C2=CC=CC=C2)COC3=CC(OC)=C(C(OC)=C3)CN4CCCC[C@H]4C(NCCOCCOCCNC(C5=CN=C(N=C5)N6CCN(CC6)C(CCOC[C@@H](NC7=C(C(NN=C7)=O)C(F)(F)F)C)=O)=O)=O
Molecular Formula
C55H69F3N10O10
Molecular Weight
1087.19
References & Citations
[1]Gao Y, et al., Novel Bifunctional Conjugates Targeting PD-L1/PARP7 as Dual Immunotherapy for Potential Cancer Treatment. J Med Chem. 2024 Jun 24.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PARP7
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
